Bibliography
- Kessler RC , ChiuWT, DemlerO, MerikangasKR, WaltersEE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry62(6) , 617–627 (2005).
- Trivedi MH , RushAJ, WisniewskiSR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1) , 28–40 (2006).
- Rush AJ , TrivediMH, WisniewskiSR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11) , 1905–1917 (2006).
- de Leon J , ArmstrongSC, CozzaKL. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics47(1) , 75–85 (2006).
- Mrazek DA . Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. The context of genetic testing in clinical psychiatric practice. CNS Spectr.11(Suppl. 3) , 3–4 (2006).
- Chung WH , HungSI, HongHS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428(6982) , 486 (2004).
- Hung SI , ChungWH, JeeSH et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16(4) , 297–306 (2006).
- Daly AK , DonaldsonPT, BhatnagarP et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet.41(7) , 816–819 (2009).
- Katsanis SH , JavittG, HudsonK. Public health. A case study of personalized medicine. Science320(5872) , 53–54 (2008).